Recombinant Human MIP-4/CCL18 是一种 CC 趋化因子配体，为中性的 CCR3 拮抗剂，与炎症反应有关。
Synonyms
rHuMIP-4/CCL18; C-C motif chemokine 18; AMAC-1; SCYA18 ; 重组人 MIP-4/CCL18
Species
HumanSource
E. coli Accession
P55774 Gene ID
6362 Molecular Weight
Approximately 7.9 kDa AA Sequence
AQVGTNKELC CLVYTSWQIP QKFIVDYSET SPQCPKPGVI LLTKRGRQIC ADPNKKWVQK YISDLKLNA Biological Activity
Full biological activity determined by a chemotaxis bioassay using human T-lymphocytes is in a concentration of 1.0-10 ng/ml. Appearance
Lyophilized powder. Formulation
Lyophilized after extensive dialysis against 20 mM PB, pH 7.4, 100 mM NaCl. Endotoxin Level
<1 EU/μg, determined by LAL method. Reconstitution
Reconstitute the lyophilized recombinant Human MIP-4/CCL18 (rHuMIP-4/CCL18) to 0.1-1.0 mg/mL using sterile distilled water or aqueous buffer containing 0.1% BSA. Storage & Stability
Lyophilized recombinant Human MIP-4/CCL18 (rHuMIP-4/CCL18) is stored at -20°C. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer. It is recommended to freeze aliquots at -20°C or -80°C for extended storage. Shipping
Room temperature in continental US; may vary elsewhere. Background
MIP-4/CCL18 is a CC chemokine ligand, acts as a neutral CCR3 antagonist, and is involved in inflammatory response. CCL18 is originally discovered as pulmonary and activation-regulated chemokine (PARC), dendritic cell (DC)-chemokine 1 (DC-CK1), alternative macrophage activation-associated CC chemokine-1 (AMAC-1), and macrophage inflammatory protein-4 (MIP-4). Enhanced CCL18 production has been demonstrated in several diseases, including various malignancies and inflammatory joint, lung, and skin diseases[1]. |
